Clay L. Efferson

Immunology and Microbiology · Life Sciences

13h-index619citations48works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(20), Monoclonal and Polyclonal Antibodies Research(10), PI3K/AKT/mTOR signaling in cancer(7), Immune Cell Function and Interaction(7), Prostate Cancer Treatment and Research(6)

Publications48 total

Supplementary Figures 1-3, Tables 1-2 from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
Supplementary Tables 1-5, Figure Legends 1-3 from Taxol Increases the Amount and T Cell–Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells
2023Open Access
Data from Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a <i>Pten</i>-Deficient Mouse Model of Prostate Cancer
2023Open Access
Data from Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma
2023Open Access
Data from Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma
2023Open Access
Supplementary Figures 1-3 from Taxol Increases the Amount and T Cell–Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells
2023Open Access
Supplementary Methods from Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma
2023Open Access
Supplementary Figures 1-4 from Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a <i>Pten</i>-Deficient Mouse Model of Prostate Cancer
2023Open Access
Data from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
Supplementary Methods from Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma
2023Open Access
Data from Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a <i>Pten</i>-Deficient Mouse Model of Prostate Cancer
2023Open Access
Data from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
Data from Taxol Increases the Amount and T Cell–Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells
2023Open Access
Supplementary Tables 1-5, Figure Legends 1-3 from Taxol Increases the Amount and T Cell–Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells
2023Open Access
Supplementary Figures 1-3, Tables 1-2 from Downregulation of Notch Pathway by a γ-Secretase Inhibitor Attenuates AKT/Mammalian Target of Rapamycin Signaling and Glucose Uptake in an ERBB2 Transgenic Breast Cancer Model
2023Open Access
Data from Taxol Increases the Amount and T Cell–Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells
2023Open Access
Supplementary Figures 1-3 from Taxol Increases the Amount and T Cell–Activating Ability of Self-Immune Stimulatory Multimolecular Complexes Found in Ovarian Cancer Cells
2023Open Access
Supplementary Figures 1-4 from Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a <i>Pten</i>-Deficient Mouse Model of Prostate Cancer
2023Open Access
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors
Translational Oncology·2012· 26 citedOpen Access
A peptidoglycan monomer with the glutamine to serine change and basic peptides bind in silico to TLR-2 (403–455)
Cancer Immunology Immunotherapy·2010· 12 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Constantin G. Ioannides(28), Jennifer Tammam(16), Kouichiro Kawano(16), Pradip K. Majumder(15), Naotake Tsuda(15), John F. Reilly(14), James L. Murray(12), Soldano Ferrone(12), Adolfo Garcı́a-Sastre(11), Minilik Angagaw(8), Xinhui Wang(8), Christopher Winter(7), Giulio Draetta(7), Peter R. Strack(7), Weisheng Zhang(7), Christopher Ware(6), Edwin Clark(6), Cyrille Sur(6), Takashi Mine(6), Christopher T. Winkelmann(5)